Federal Appeals Court Orders FDA to Reconsider E-Cigarette Marketing Ban

Regulations by 2FIRSTS.ai

Jan.05.2024

Federal Appeals Court Orders FDA to Reconsider E-Cigarette Marketing Ban

US appeals court orders FDA to reconsider ban on e-cigarette flavor marketing plans, overturning previous decision made in July 2022.

Reuters reported on January 3rd that the Federal Appeals Court ordered the U.S. Food and Drug Administration (FDA) to reconsider its decision to ban the marketing plans of two e-cigarette e-liquid manufacturers.

The decision was made by a court based in New Orleans, with 5 out of 9 judges voting to overturn the ban that was imposed in July 2022.

The court, led by Judge Andrew Oldham, appointed by former Republican President Donald Trump, has ruled in a majority vote that the FDA requested e-cigarette manufacturers to provide detailed marketing plans to prevent teenage abuse. However, they later rejected their marketing plans without conducting a review.

Oldham pointed out that this does not comply with the FDA's obligation to "hold businesses accountable.

The lawyers representing e-cigarette manufacturers, Triton Distribution Company and Vapetasia LLC, expressed satisfaction with the court's decision, hoping that it will prompt the FDA to provide clear instructions on how businesses should obtain marketing authorization.

References:

[1] La FDA doit reconsidérer son refus d'approuver les produits de vapotage

Also Read:

[1] JUUL Labs Seeks FDA Authorization for Mint Flavored E-Cigarette Pods

[2] FDA Issues Warnings to Online Retailers Selling Unauthorized E-cigarette Products

[3] FDA CTP Releases Comprehensive Strategic Plan for Next 5 Years

[4] FDA Urged Reformation of PMTA Process

#North America #United States #Legislation #E-liquids #FDA #Court case #E-cigarette #E-cigarettes and Tobacco #E-cigarette Market #Marketing

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most

In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.

Oct.21

2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape

Overseas e-cig brands are embracing “for her” designs, turning devices into fashion accessories. 2Firsts notes a new “pink tax” emerging through design and pricing, reflecting shifting gender and branding strategies.

Oct.20

KT&G to Complete New Indonesian Factory, Its Largest Overseas Production Hub

According to Daily Hankooki, KT&G’s new factory in Indonesia will be completed this month and is scheduled to begin operations in February 2026. Once operational, the facility will have an annual production capacity of around 35 billion cigarettes, becoming the company’s largest overseas manufacturing base.

Nov.12 by 2FIRSTS.ai

VCU Tests Nearly 1,300 School-Confiscated Vapes, Finding Mislabeling, Mixed Cannabinoids and Contamination

New research from Virginia Commonwealth University (VCU) found microbial contamination — including coliform, a bacteria indicating fecal exposure — in some vaping devices confiscated from U.S. schools. However, researchers stressed that newly purchased, unopened vapes showed no such contamination. The findings point to risks linked to unregulated products and improper storage conditions, reinforcing the importance of regulated supply chains and product authentication.